GlassScriptPhysician profile
Sulejman Celaj
NPI 1376717793
$35,782.17
in general payments reported to CMS, 2019-2025
33 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,769 · 2021: $3,795 · 2022: $3,028 · 2023: $2,472 · 2024: $4,183 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,133 · Honoraria: $1,200 · Travel and Lodging: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,133.06 |
| Honoraria | $1,200.00 |
| Travel and Lodging | $322.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,965.30 | 2019-2024 | Perclose Prostyle, Mitraclip |
| Chiesi USA, INC. | $6,612.04 | 2019-2024 | Juxtapid |
| Medtronic, INC. | $6,372.76 | 2021-2025 | Symplicity G3, Onyx Frontier, Micra |
| Angiodynamics, INC. | $2,464.94 | 2019 | |
| Medtronic Vascular, INC. | $1,569.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,156.96 | 2019-2025 | |
| Novo Nordisk INC | $1,131.36 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,014.33 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $897.01 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $893.80 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Cardiovascular Systems INC. | $776.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $770.96 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Welch Allyn | $765.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $493.66 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $475.71 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $343.09 | 2020-2022 | |
| Scpharmaceuticals INC. | $321.39 | 2023-2025 | |
| Heartflow, INC. | $289.73 | 2025 | |
| Janssen Scientific Affairs, LLC | $280.13 | 2019-2024 | |
| Philips North America LLC | $195.57 | 2023-2025 | Igt Devices Undivided, Mcot |
| Biotronik INC. | $183.79 | 2022 | |
| Stryker Corporation | $167.20 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Flowtriever |
| Inari Medical, INC. | $159.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biosense Webster, INC. | $121.58 | 2022 | |
| Merck Sharp & Dohme LLC | $98.48 | 2023-2025 | Verquvo |
| Terumo Medical Corporation | $66.18 | 2022 | |
| Amgen INC. | $53.08 | 2019 | |
| Celgene Corporation | $40.85 | 2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.12 | 2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $19.11 | 2024 | |
| Edwards Lifesciences Corporation | $18.81 | 2019 | |
| Pfizer INC. | $16.00 | 2020 | |
| Glaxosmithkline, LLC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sulejman Celaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.